{
    "clinical_study": {
        "@rank": "24927", 
        "arm_group": [
            {
                "arm_group_label": "febuxostat group", 
                "arm_group_type": "Experimental", 
                "description": "oral"
            }, 
            {
                "arm_group_label": "allopurinol group", 
                "arm_group_type": "Active Comparator", 
                "description": "oral"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a multicenter, open label, randomized, allopurinol-controlled, parallel-design\n      study. Approximately 120 subjects will be randomly assigned in 1:1 ratio to receive\n      febuxostat, or allopurinol for subjects with gout."
        }, 
        "brief_title": "A Study to Evaluate Safety and Efficacy of Oral Febuxostat in Patients With Gout", 
        "completion_date": {
            "#text": "February 2012", 
            "@type": "Actual"
        }, 
        "condition": "Gout", 
        "condition_browse": {
            "mesh_term": "Gout"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subjects will also have a history or presence of gout as defined by the American\n             College of Rheumatology (ACR) criteria\n\n          -  Subject has serum urate level >= 8.0 mg/dL at the screening Visit\n\n        Exclusion Criteria:\n\n          -  Female subject who is breast-feeding or pregnant\n\n          -  Subject has a history of xanthinuria\n\n          -  Subject who is intolerant of allopurinol, ie hypersensitivity, Steven-Johnson\n             syndrome/topic epidermal necrolysis\n\n          -  Subject who takes allopurinol > 300 mg/day and with serum urate level > 8mg/dL\n\n          -  Subject who is HLA B*5801 positive\n\n          -  Subject who is receiving thiazide diuretic therapy\n\n          -  Subject who has secondary hyperuricemia\n\n          -  Subject who requires concurrent therapy with any systemic or topical medications,\n             prescribed or non-prescribed, containing aspirin or other salicylates (low doses of\n             aspirin will be allowed(ie. =< 325mg/day)\n\n          -  Subject who requires therapy with prednisone > 10 mg/ day during the study\n\n          -  Subject who has active liver disease or hepatic dysfunction, defined as both ALT and\n             AST > 1.5 times the upper limit of normal\n\n          -  Subject who has serum creatinine >= 1.5mg/dL\n\n          -  Subject who has any another significant medical condition as defined by the\n             investigator that would interfere with the treatment, safety or compliance with the\n             protocol (eg. A clinically significant ECG result)\n\n          -  Subject who has a history of cancer (other than basal cell carcinoma of the skin)\n             within 5 years prior to the study, or has taken any systemic cancer chemotherapy\n             within 5 years prior to the study\n\n          -  Subject who has previously participated in a clinical study in which febuxostat was\n             administered\n\n          -  Subject who has participated in another investigational trial within the 30 days\n             prior to the study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "109", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "November 27, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01736514", 
            "org_study_id": "TMXALL-1001-TW"
        }, 
        "intervention": [
            {
                "arm_group_label": "febuxostat group", 
                "description": "oral", 
                "intervention_name": "febuxostat", 
                "intervention_type": "Drug", 
                "other_name": "Adenuric, Uloric, Feburic"
            }, 
            {
                "arm_group_label": "allopurinol group", 
                "description": "oral", 
                "intervention_name": "Allopurinol", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Allopurinol", 
                "Febuxostat"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "xanthine oxidase inhibitor", 
            "Uric acid lowering drug"
        ], 
        "lastchanged_date": "November 27, 2012", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Kaohsiung", 
                        "country": "Taiwan"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Linkou", 
                        "country": "Taiwan"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Taichung", 
                        "country": "Taiwan"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Taipei", 
                        "country": "Taiwan"
                    }
                }
            }
        ], 
        "location_countries": {
            "country": "Taiwan"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized, Open Label, Multicenter, Allopurinol- Controlled Study to Assess the Safety and Efficacy of Oral Febuxostat in Patients With Gout", 
        "overall_official": {
            "affiliation": "Astellas Pharma Taiwan, Inc.", 
            "last_name": "Medical Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Taiwan: Department of Health", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "February 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Proportion of subjects whose serum urate level decreases to < 6.0 mg/dL", 
            "safety_issue": "No", 
            "time_frame": "week 12"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01736514"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Percent reduction in serum urate levels", 
                "safety_issue": "No", 
                "time_frame": "Baseline and at week 12"
            }, 
            {
                "measure": "Safety assessed by the incidence of adverse events, physical exam. and vital signs, tabo-tests and 12-lead ECG", 
                "safety_issue": "No", 
                "time_frame": "Baseline and at week 12"
            }
        ], 
        "source": "Astellas Pharma Inc", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Astellas Pharma Taiwan, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2011", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2012"
    }
}